

# Mark Crowther

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9568420/publications.pdf>

Version: 2024-02-01

185  
papers

26,233  
citations

20759

60  
h-index

6113

159  
g-index

193  
all docs

193  
docs citations

193  
times ranked

20269  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2012, 141, e419S-e496S.	0.4	3,745
2	Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2008, 133, 160S-198S.	0.4	1,926
3	Executive Summary. <i>Chest</i> , 2012, 141, 7S-47S.	0.4	1,452
4	Oral Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e44S-e88S.	0.4	1,323
5	Evidence-Based Management of Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e152S-e184S.	0.4	1,105
6	Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. <i>Critical Care Medicine</i> , 2005, 33, 1565-1571.	0.4	957
7	Systematic Overview of Warfarin and Its Drug and Food Interactions. <i>Archives of Internal Medicine</i> , 2005, 165, 1095.	4.3	931
8	Treatment and Prevention of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2012, 141, e495S-e530S.	0.4	860
9	Myocardial Injury after Noncardiac Surgery. <i>Anesthesiology</i> , 2014, 120, 564-578.	1.3	740
10	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
11	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
12	Diagnosis of DVT. <i>Chest</i> , 2012, 141, e351S-e418S.	0.4	570
13	Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 142.	3.8	511
14	Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. <i>Cmaj</i> , 2008, 179, 417-426.	0.9	484
15	Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1128-1139.	1.2	414
16	Dalteparin versus Unfractionated Heparin in Critically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 364, 1305-1314.	13.9	382
17	Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 2381-2391.	1.6	359
18	Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. <i>American Journal of Hematology</i> , 2012, 87, S141-5.	2.0	320

#	ARTICLE	IF	CITATIONS
19	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. <i>Thrombosis Research</i> , 2009, 123, 687-696.	0.8	300
20	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2011, 106, 429-438.	1.8	295
21	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , 2018, 378, 699-707.	13.9	294
22	The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. <i>Blood</i> , 2014, 124, 2450-2458.	0.6	290
23	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. <i>Critical Care Medicine</i> , 2021, 49, e219-e234.	0.4	289
24	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. <i>Chest</i> , 2017, 151, 127-138.	0.4	245
25	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 32-67.	1.0	243
26	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. <i>American Journal of Hematology</i> , 2019, 94, 697-709.	2.0	225
27	Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1993.	3.8	221
28	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. <i>Chest</i> , 2012, 141, 53S-70S.	0.4	213
29	Indications, Complications, and Management of Inferior Vena Cava Filters. <i>JAMA Internal Medicine</i> , 2013, 173, 513.	2.6	209
30	Warfarin Maintenance Dosing Patterns in Clinical Practice. <i>Chest</i> , 2005, 127, 2049-2056.	0.4	197
31	Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and D-dimer Testing. <i>Annals of Internal Medicine</i> , 2001, 135, 108.	2.0	179
32	Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. <i>Annals of Internal Medicine</i> , 2013, 158, 800.	2.0	176
33	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	2.2	173
34	Combined Aspirin and Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 117.	4.3	172
35	Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis. <i>Chest</i> , 2013, 144, 1207-1215.	0.4	171
36	GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 129-141.	2.4	168

#	ARTICLE	IF	CITATIONS
37	GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 142-152.	2.4	167
38	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 842-851.	1.8	157
39	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. <i>Blood</i> , 2020, 135, 239-251.	0.6	145
40	The metabolic syndrome and the risk of venous thrombosis: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1914-1918.	1.9	144
41	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 879-890.	1.8	139
42	Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin<sub>title</sub>>An Assessment of Safety and Pharmacodynamics: The DIRECT Study<sub>title</sub>>. <i>Archives of Internal Medicine</i> , 2008, 168, 1805.	4.3	133
43	Introduction to the Ninth Edition. <i>Chest</i> , 2012, 141, 48S-52S.	0.4	129
44	A Diagnostic Strategy Involving a Quantitative Latex <sup>d</sup>-Dimer Assay Reliably Excludes Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2003, 138, 787.	2.0	120
45	A Red Blood Cell Agglutination <sup>d</sup>-Dimer Test to Exclude Deep Venous Thrombosis in Pregnancy. <i>Annals of Internal Medicine</i> , 2007, 147, 165.	2.0	119
46	Venous thromboembolic disease: An observational study in medical-surgical intensive care unit patients. <i>Journal of Critical Care</i> , 2000, 15, 127-132.	1.0	114
47	Antidotes for Novel Oral Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1736-1745.	1.1	114
48	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. <i>Blood</i> , 2012, 119, 1356-1362.	0.6	111
49	Predicting Deep Venous Thrombosis in Pregnancy: Out in &#x201c;Field?. <i>Annals of Internal Medicine</i> , 2009, 151, 85.	2.0	109
50	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1966.	3.8	106
51	Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1830-1840.	1.9	89
52	Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. <i>British Journal of Haematology</i> , 2005, 129, 803-810.	1.2	84
53	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	1.9	84
54	The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy. <i>Journal of the American College of Cardiology</i> , 2006, 47, 804-808.	1.2	81

#	ARTICLE	IF	CITATIONS
55	The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. <i>Blood Transfusion</i> , 2015, 13, 559-68.	0.3	78
56	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. <i>Blood</i> , 2014, 124, 4269-4269.	0.6	75
57	Modified Early Warning Score (MEWS) Identifies Critical Illness among Ward Patients in a Resource Restricted Setting in Kampala, Uganda: A Prospective Observational Study. <i>PLoS ONE</i> , 2016, 11, e0151408.	1.1	69
58	Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin prophylaxis: prevalence, incidence and risk factors. <i>Critical Care</i> , 2008, 12, R32.	2.5	68
59	Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 705-706.	0.4	67
60	Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1322-1333.	1.9	67
61	Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020. <i>International Journal of Stroke</i> , 2021, 16, 321-341.	2.9	64
62	Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. <i>Intensive Care Medicine</i> , 2005, 31, 48-55.	3.9	60
63	Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness. <i>Chest</i> , 2013, 144, 848-858.	0.4	60
64	Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. <i>Blood Advances</i> , 2020, 4, 5373-5377.	2.5	60
65	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	1.9	60
66	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. <i>American Journal of Hematology</i> , 2009, 84, 584-588.	2.0	56
67	Venous Thromboembolism Prophylaxis in Critically Ill Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 068-074.	1.5	50
68	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	2.5	50
69	Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review. <i>Journal of Critical Care</i> , 2009, 24, 197-205.	1.0	45
70	Non-OO blood type influences the risk of recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1172-1179.	1.8	44
71	Heparin-induced thrombocytopenia in the critically ill: Interpreting the 4Ts test in a randomized trial. <i>Journal of Critical Care</i> , 2014, 29, 470.e7-470.e15.	1.0	44
72	Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. <i>Vox Sanguinis</i> , 2017, 112, 268-278.	0.7	43

#	ARTICLE	IF	CITATIONS
73	Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. <i>Thrombosis Research</i> , 2020, 194, 240-245.	0.8	43
74	The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1956-1965.	1.9	42
75	Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 249-258.	1.0	40
76	Postdischarge venous thromboembolic complications following pulmonary oncologic resection: An underdetected problem. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 992-999.	0.4	40
77	A Randomized Trial Comparing 1 mg of Oral Vitamin K With No Treatment in the Management of Warfarin-Associated Coagulopathy in Patients With Mechanical Heart Valves. <i>Journal of the American College of Cardiology</i> , 2005, 46, 732-733.	1.2	38
78	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3155-3162.	2.5	38
79	Severe Hemolytic Anemia Post-Renal Transplantation Produced by Donor Anti-D Passenger Lymphocytes: Case Report and Literature Review. <i>Transfusion Medicine Reviews</i> , 2009, 23, 155-159.	0.9	37
80	Treatment of warfarin-associated coagulopathy with vitamin K. <i>Expert Review of Hematology</i> , 2011, 4, 657-667.	1.0	37
81	Thrombosis and anticoagulation in the setting of renal or liver disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 188-195.	0.9	37
82	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. <i>BMC Medical Research Methodology</i> , 2020, 20, 113.	1.4	37
83	Reversal of target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 195-202.	1.0	36
84	Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1926-1932.	1.9	35
85	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. <i>Thrombosis and Haemostasis</i> , 2010, 104, 118-121.	1.8	34
86	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e544-e552.	2.2	34
87	Portal Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 498-506.	0.7	32
88	The thrombogenicity of C1 esterase inhibitor (human): Review of the evidence. <i>Allergy and Asthma Proceedings</i> , 2014, 35, 444-453.	1.0	31
89	Prevention of venous thromboembolism in critically ill surgery patients: A cross-sectional study. <i>Journal of Critical Care</i> , 2001, 16, 161-166.	1.0	30
90	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	1.8	30

#	ARTICLE	IF	CITATIONS
91	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	1.5	29
92	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	2.0	28
93	Systematic review of anticoagulant treatment of catheter-related thrombosis. <i>Thrombosis Research</i> , 2015, 136, 1103-1109.	0.8	28
94	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , 2018, 162, 104-109.	0.8	27
95	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. <i>Current Oncology</i> , 2021, 28, 5434-5451.	0.9	26
96	The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. <i>Contemporary Clinical Trials</i> , 2010, 31, 131-133.	0.8	25
97	Rapid quantitative D-dimer to exclude pulmonary embolism: a prospective cohort management study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 504-509.	1.9	25
98	Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. <i>Journal of Thoracic Disease</i> , 2017, 9, 80-87.	0.6	25
99	A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. <i>Blood Advances</i> , 2020, 4, 728-739.	2.5	25
100	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	1.0	25
101	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2274-2286.	1.9	24
102	Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit. <i>Critical Care</i> , 2014, 18, R82.	2.5	23
103	Andexanet Alfa for Factor Xa Inhibitor Reversal. <i>New England Journal of Medicine</i> , 2016, 375, 2498-2500.	13.9	22
104	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <i>European Journal of Epidemiology</i> , 2016, 31, 541-561.	2.5	21
105	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	2.2	21
106	Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial. <i>Academic Emergency Medicine</i> , 2022, 29, 150-158.	0.8	19
107	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. <i>Thrombosis and Haemostasis</i> , 2022, 122, 998-1005.	1.8	19
108	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	0.8	18



#	ARTICLE	IF	CITATIONS
109	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017, 160, 97-104.	0.8	18
110	Frequency of arterial thromboembolism in populations with malignancies: A systematic review. <i>Thrombosis Research</i> , 2019, 184, 16-23.	0.8	18
111	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. <i>Journal of Biological Chemistry</i> , 2017, 292, 21180-21192.	1.6	17
112	Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2017, 2017, 1-11.	0.3	17
113	Fibrin and Thrombin Sealants in Vascular and Cardiac Surgery: A Systematic Review and Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 60, 469-478.	0.8	16
114	Specific antidotes for bleeding associated with direct oral anticoagulants. <i>BMJ: British Medical Journal</i> , 2017, 357, j2216.	2.4	15
115	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , 2018, 8, e021900.	0.8	15
116	A systematic review of the association between anti- $\beta_2$ -glycoprotein I antibodies and APS manifestations. <i>Blood Advances</i> , 2021, 5, 3931-3936.	2.5	15
117	Approaches to Diagnosing and Managing Anticoagulant-Related Bleeding. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 702-710.	1.5	14
118	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 184, 58-61.	0.8	14
119	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	1.8	14
120	Intensity of Warfarin Coagulation in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2010, 12, 64-69.	2.1	13
121	Phase 4 research: what happens when the rubber meets the road?. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 15-18.	0.9	13
122	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. <i>American Journal of Medicine</i> , 2016, 129, e247-e248.	0.6	13
123	Symposium 4: Hot topics in parenteral nutrition A review of the use of glutamine supplementation in the nutritional support of patients undergoing bone-marrow transplantation and traditional cancer therapy. <i>Proceedings of the Nutrition Society</i> , 2009, 68, 269-273.	0.4	12
124	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	2.0	11
125	Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2308-2317.	1.9	10
126	Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. <i>Hematology</i> , 2020, 25, 112-117.	0.7	10



#	ARTICLE	IF	CITATIONS
127	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	1.5	8
128	Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial. <i>Blood</i> , 2019, 134, 3685-3685.	0.6	8
129	Newer Anticoagulants in Critically Ill Patients. <i>Critical Care Clinics</i> , 2012, 28, 427-451.	1.0	7
130	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 480-485.	1.8	7
131	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 671-681.	1.5	7
132	Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). <i>Blood Advances</i> , 2020, 4, 2460-2467.	2.5	7
133	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	0.7	7
134	Comment on: Editorial by Husted et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel” <i>Thrombosis and Haemostasis</i> , 2014, 112, 841-841.	1.8	6
135	Aspirin in secondary prevention of recurrent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 392-394.	1.0	6
136	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. <i>CMAJ Open</i> , 2017, 5, E594-E603.	1.1	6
137	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. , 2017, , 223-233.		6
138	Definition of major bleeding used by US anticoagulation clinics. <i>Thrombosis Research</i> , 2009, 124, 239-240.	0.8	5
139	A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. <i>BMC Hematology</i> , 2016, 16, 17.	2.6	5
140	Andexanet alfa for the treatment of hemorrhage. <i>Expert Review of Hematology</i> , 2018, 11, 847-855.	1.0	5
141	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , 2018, 101, 362-367.	1.1	5
142	Double Blind Pilot Randomized Trial Comparing Extended Anticoagulation to Placebo Following Major Lung Resection for Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 1123-1134.	0.4	5
143	The Safety of Co-Administered Low-Molecular-Weight Heparin and Continuous Epidural Analgesia after Major Orthopedic Surgery: Assessment of a Standardized Management Protocol.. <i>Blood</i> , 2004, 104, 704-704.	0.6	5
144	Case Report: Two Cases of Strongyloidiasis Presenting with Thrombotic Events. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 418-421.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Iron chelation therapy in patients with low-to intermediate-risk myelodysplastic syndrome: A systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2022, 197, .	1.2	5
146	Low prevalence of <i>JAK2</i> V617F mutation in patients with first unprovoked venous thromboembolism. <i>British Journal of Haematology</i> , 2011, 155, 511-513.	1.2	4
147	North America anticoagulation forum guidance on reversal of direct oral anticoagulants. <i>European Journal of Internal Medicine</i> , 2019, 67, 30-32.	1.0	4
148	Iron supplementation following bariatric surgery: A systematic review of current strategies. <i>Obesity Reviews</i> , 2021, 22, e13268.	3.1	4
149	Reduced-dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: A systematic review and meta-analysis—Response to Commentary. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2359-2360.	1.9	4
150	Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of CrCl <math>\geq 30\text{ mL/Min}</math> from the Trivet Study. <i>Blood</i> , 2016, 128, 90-90.	0.6	4
151	Antiphospholipid Syndrome: A Challenging Hypercoagulable State with Systemic Manifestations. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 669-676.	0.9	3
152	Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our Preconceptions. <i>Journal of General Internal Medicine</i> , 2016, 31, 147-148.	1.3	3
153	Severe coagulopathy after a massasauga rattlesnake bite. <i>Cmaj</i> , 2018, 190, E191-E194.	0.9	3
154	Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12724.	1.0	3
155	Treatment of Antiphospholipid Antibody Syndrome—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 42.	3.8	2
156	Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 96-96.	1.0	2
157	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 242-266.	1.0	2
158	Antithrombotic Agents. , 2013, , 477-495.		2
159	The value of bleeding scores in the assessment of patients presenting with bleeding of unknown cause: Complex algorithms with little predictive value. <i>European Journal of Internal Medicine</i> , 2020, 78, 26-27.	1.0	2
160	Equity and game theory strategies to promote gender diversity and inclusion in an academic health science center. <i>CJC Open</i> , 2021, 3, S53-S61.	0.7	2
161	Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. <i>Expert Review of Hematology</i> , 2009, 2, 357-360.	1.0	1
162	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, xiii-xiv.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Thrombosis. , 2013, , 67-77.		1
164	American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response. Chest, 2013, 143, 1191.	0.4	1
165	The risk of venous thromboembolism in patients with clinically overt gastrointestinal bleeding. American Journal of Hematology, 2018, 93, E42-E45.	2.0	1
166	Evaluating the quality of systematic reviews and meta-analyses published on direct oral anticoagulants in the past 5 years. BMJ Evidence-Based Medicine, 2020, , bmjebm-2019-111326.	1.7	1
167	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. Blood, 2019, 134, 711-711.	0.6	1
168	2009 evidence-based clinical practice guidelines for diagnosing a first episode of lower extremities deep vein thrombosis in ambulatory outpatients. , 2009, 119, 541-9.		1
169	Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review. Thrombosis Research, 2022, 213, 16-26.	0.8	1
170	The clinical consequence of subtherapeutic anticoagulation: the low INR study (LINeRS). Journal of Thrombosis and Thrombolysis, 2008, 25, 127-128.	1.0	0
171	Preventing and managing bleeding complications in anticoagulated patients: A case based approach. Thrombosis Research, 2008, 123, S42-S45.	0.8	0
172	Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit. Evidence-Based Medicine, 2012, 17, 154-155.	0.6	0
173	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	1.0	0
174	Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. Annals of Pharmacotherapy, 2015, 49, 125-126.	0.9	0
175	The direct oral anticoagulants: can we finally stop using rat poison?. Blood Advances, 2017, 1, 980-980.	2.5	0
176	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2018, 45, 578-587.	1.0	0
177	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	0
178	The Management of Anticoagulated Patients Requiring Dental Extraction: A Cross-Sectional Survey of Oral Surgeons and Hematologists.. Blood, 2006, 108, 629-629.	0.6	0
179	Use of Therapeutic Dose Low Molecular Weight Heparin in Patients with Renal Insufficiency: Analysis of Anti-Xa Levels and Creatinine Clearance.. Blood, 2006, 108, 884-884.	0.6	0
180	Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis. Blood, 2016, 128, 88-88.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. Blood, 2018, 132, 2518-2518.	0.6	0
182	Evaluating the Quality of Systematic Reviews & Meta-Analyses Published on Direct Oral Anticoagulants in the Past 5 Years. Blood, 2019, 134, 5802-5802.	0.6	0
183	Iron Chelation Therapy in Low- to Intermediate- Risk Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4661-4661.	0.6	0
184	Thrombotic Events in COVID-19 Patients Undergoing Convalescent Plasma Therapy: A Systematic Review. Blood, 2021, 138, 3221-3221.	0.6	0
185	New anticoagulants: an update. Clinical Advances in Hematology and Oncology, 2004, 2, 743-9.	0.3	0